Table 6. Demographics, risk factors, and anticoagulation for IDDVT, PDVT ± DDVT, and PE ± any DVT, reported in observational VTE studies.
|
Barco et al
13
Single-center, retrospective N = 831 Italy, 2000–2012 |
RIETE,
14
N
= 11,086
24 countries worldwide 2001–2008 |
OPTIMEV,
15
N
= 1,643
France, 2004–2006 |
GARFIELD-VTE,
16
N
= 10,088
28 countries worldwide 2014–2017 |
RE-COVERY DVT/PE,
N
= 5,722
34 countries worldwide 2016–2017 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDDVT | PDVT | IDDVT | PDVT | IDDVT | PDVT | IDDVT | PDVT | PE | IDDVT | PDVT | PE | |
| Patients, n (%) | 202 (24.3) | 629 (75.7) | 1,921 (17.3) | 9,165 (82.7) | 933 (56.8) | 710 (43.2) | 2,145 (21.3) | 3,846 (38.1) | 4,097 (40.6) | 1,016 (17.6) | 2,305 (39.9) | 2,415 (42.5) |
| Female, % | 56 | 49 | 49 | 48 | 58 | 52 | 52 | 49 | 49 | 51 | 47 | 51 |
| Age, mean or median, years | 66 | 67 | 65 | 70 | 62 | 69 | 56 | 58 | 60 | 58 | 62 | 63 |
| Caucasian ethnicity, % | – | – | – | – | – | – | 69.1 | 64.1 | 73.6 | 81.7 | 78.6 | 70.9 |
| Risk factors, % | ||||||||||||
| History of VTE | 3 a | 5 a | 15 | 17 | 29 | 34 | 14 | 17 | 15 | 11 | 13 | 10 |
| Active cancer | 24 | 23 | 14 | 22 | 11 | 20 | 7 | 10 | 10 | 8 | 10 | 12 |
| Trauma/surgery | 14/21 | 9/17 | –/15 | –/11 | –/22 | –/12 | 13/15 | 9/11 | 5/13 | 6 (either) | 7 (either) | 8 (either) |
| Immobilization | 23 | 17 | 24 | 28 | 18 | 20 | – | – | – | 4 | 3 | 2 |
| Anticoagulation therapy, % | ||||||||||||
| Any anticoagulant | 97 | 88 | 97 b | 97 b | 81 c | 92 c | 97 d | 98 d | 98 d | – | – | – |
| OAC | 32 | 73 | – | – | – | – | – | – | – | – | – | – |
| VKA | – | – | – | – | 70 c | 70 c | 24 d | 31 d | 30 d | 24 e | 22 e | 24 e |
| NOAC | – | – | – | – | – | – | 50 d | 46 d | 47 d | 56 e | 55 e | 53 e |
| Parenteral only | – | – | – | – | – | – | 17 d | 16 d | 16 d | 20 e | 21 e | 18 e |
Abbreviations: DDVT, distal DVT; DVT, deep vein thrombosis; GARFIELD-VTE: The Global Anticoagulant Registry in the FIELD-Venous Thromboembolic Events; IDDVT, isolated DDVT; NOAC, non-VKA oral anticoagulant; OAC, oral anticoagulant; OPTIMEV: OPTimisation de l'Interrogatoire dans l'évaluation du risque throMbo-Embolique Veineux; PDVT, proximal DVT; PE, pulmonary embolism; RIETE: Registro Informatizado de pacientes con Enfermedad TromboEmbólica; VKA, vitamin K antagonist; VTE, venous thromboembolism.
a
Family history of VTE.
b
For ≥10 days.
c
For 3-month follow-up period.
d
For ≤30 days.
e
Up to hospital discharge or 14 days after diagnosis (whichever was later).